JUNE 2011   

XXIst Regional Congress of the ISBT
June 18 - 23
Lisbon, Portugal

7th IABS Symposium on Advances in Transfusion Safety
July 15 - 17

International Symposium on Critical Bleeding (ISCB)
September 5-6
Copenhagen, Denmark


ISBT Symposium
Tuesday June 21, 2011,
12.30 - 14.30  Auditorium I

"Pathogen Inactivation In
Practice : INTERCEPT
Platelets and Plasma for
Support of Routine and
Special Care Patients"

Dr. Matilde Santos, Chair
(Lisbon, Portugal)

Dr. Miguel Lozano
( Barcelona, Spain)

Dr. Andreas Buser
(Basel, Switzerland)

Dr. Daniel Kientz
(Strasburg, France)

INTERCEPT Activities at ISBT June 18-23rd
ISBT Lisbon will soon be underway. We look forward to welcoming you to our booth in the exhibition hall (#443) and to our lunch symposium on June 21st. In addition, recent INTERCEPT data will be featured during oral and poster presentations.

Symposium : Tuesday June 21, 2011, 12.30 - 14.30  Auditorium I

Oral Presentation:

  • Tuesday, June 21st, 9:45 - 10:00 am - [4A-S15-03] Validation and Implementation of the INTERCEPT Blood System for Platelets for Pathogen Inactivation of Apheresis and Buffy-Coat Products at One of the Biggest Regional Blood-Centers of Switzerland.
    D Goslings, P Lodemann, G Yavuzcan et al.

Posters: The INTERCEPT Blood System for platelets, plasma and red blood cells will be the focus of numerous posters addressing the following concepts:
  • Validation and implementation of INTERCEPT platelets
  • Validation of double dose buffy coat platelets treated with INTERCEPT
  • Hemostatic efficacy of INTERCEPT platelets stored for 5 & 7 days
  • In vitro evaluation of previously frozen plasma treated with INTERCEPT
  • Impact of holding conditions on coagulation parameters for INTERCEPT plasma
  • In vitro evaluation of INTERCEPT RBC
Visit our website for a complete guide of INTERCEPT activities at ISBT 

E.coli Outbreak Puts Spotlight on Blood AvailabilityE.coli
In one of the largest outbreaks on record, Germany has been the hardest hit by confirmed cases of hemolytic-uremic syndrome (HUS) as a result of exposure to EHEC, a new strain of E. coli. With dozens of patients in critical care and requiring large volumes of plasma, timely availability of plasma is critical. The widespread use of plasma quarantine in several EU countries including Germany means that newly collected plasma can’t be released for at least 4 months, and as a result, such outbreaks have the potential to strain the blood supply if increased demand levels persist for an extended period of time. In contrast, INTERCEPT plasma can be released immediately after treatment.

Read more
Read WHO alert

INTERCEPT Red Cell Program Progresses Toward Phase 3 Clinical Trial

Safety and viability assessments of INTERCEPT treated RBCs have recently been published in Transfusion (e-pub ahead of print). The safety evaluation, part of the preclinical program for INTERCEPT RBC, concluded that the level of residual S-303 and S-300 in the treated RBC unit is well below that at which no adverse risks were observed. RBC viability was characterized in a phase 1 clinical trial that found INTERCEPT-treated RBCs to be physiologically and metabolically suitable for transfusion after 35 days of storage and met FDA guidance criteria for 24-hour recovery. Based on these results, a phase 3 clinical trial is planned in collaboration with the French national transfusion service and the German Red Cross in Frankfurt.

Read the safety study abstract
Read the phase 1 trial abstract

UK Sees Increase in Imported Cases of Illness From Vector Borne Pathogens mosquito laying eggs courtesy of phil.cdc.edu

Within the past 2 years, recorded dengue fever infections doubled among UK residents, while both malaria and chikungunya saw an average increase of 30%. Of the confirmed cases of dengue fever, those with recent travel predominately visited destinations in Southeast Asia, the Indian Subcontinent and Thailand. Malaria was frequently connected to residents traveling to West Africa, South Asia or India. Adoption of pathogen inactivation may provide a safe means to relax donor deferrals despite recent travel abroad.

Read the BBC malaria article
Read the Health Protection Agency press release for Dengue

Pathogen Spotlight: Borrelia burgdorferi (Lyme Disease)Borrelia burgdorferi courtesy of phil.ece.gov

Borrelia burgdorferi is a spirochete bacterium that is the causative agent of Lyme borreliosis (Lyme disease), the most prevalent arthropod-transmitted infection in Northern Europe, temperate Asia and North America (Smith R. 2006).  Borrelia is transmitted by ticks of the Ixodes genus and reservoir species including birds, several strains of mice, deer, voles and lizards. Lyme borreliosis is a multisystem infection with several stages, including asymptomatic phases, and rather non-specific symptoms that can mimic other infections.  While the disease is easily treatable with antibiotics in the early stage, chronic infection is both more difficult to diagnose and more difficult to treat.

Chronic infections that may include long asymptomatic periods make Borrelia a risk for contamination of donated blood and make donor questions unreliable as a screening tool.  In addition, several studies have demonstrated the survival of B. burgdorferi for up to 45 days in blood components treated and stored according to modern blood banking practices (Badon 1989, Johnson 1990, Nadelman 1990), confirming it as a potential risk for transfusion transmission.  There is no commercially available assay for use in blood screening, but B. burgdorferi is very susceptible to inactivation by the INTERCEPT Blood System; approved claims include inactivation of >6.8 logs in platelets and >10.6 logs in plasma. For a comprehensive review of Lyme borreliosis see Hengge, et al. 2003.

Read the INTERCEPT Technical Data Sheets

Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk
Jenkins C, Ramírez-Acros S, Goldman M, Devine D
Transfusion : 26 May 2011. [Epub ahead of print]

Read abstract

Update on the status of pathogen inactivation methods
AuBuchon, J.P.
ISBT Science Series: 2011 (6), 181–188
DOI: 10.1111/j.1751-2824.2011.01471.x

Read abstract

Travel-related Dengue Virus Infection, the Netherlands, 2006–2007
Baaten G, Sonder G, Zaaijer H, et al
EID Journal Home: May 2011;17(5)
DOI: 10.3201/eid1705.101125

Read abstract

XMRV, Q fever and other emerging infections: impact on management of blood safety
Dodd, R.Y.
ISBT Science Series: 2011 (6), 119–123
DOI: 10.1111/j.1751-2824.2011.01454.x

Read abstract

Use of INTERCEPT is contraindicated in patients with a history of allergic response to amotosalen or psoralens.
No pathogen inactivation system has been shown to inactivate all pathogens.
This newsletter may contain links to material from individuals and organizations other than Cerus and its employees. These statements and material are not to be considered as made or endorsed by Cerus.

e-mail: customer_services@cerus.com  |  www.interceptbloodsystem.com  |  www.cerus.com
Not approved for sale in U.S.
Cerus, INTERCEPT Blood System, and INTERCEPT are trademarks of Cerus Corporation.

Forward Email
Remove me from this list